SEMAX, SELANK, ADAMAX, and DIHEXA appear together naturally when researchers browse neuro-research catalogs, but they should not be treated as four interchangeable versions of the same idea. Their names refer to different compounds or catalog identities, their published evidence bases are different, and the strength of independent information available for each one varies substantially.
For a laboratory or procurement reader, the useful questions are therefore not simply “which one is better?” or “which one is stronger?” The more defensible questions are: What exactly does each name identify? What format is being sold? What documentation accompanies the lot? What has actually been studied in peer-reviewed literature? And where does the evidence stop?
Affiliate disclosure: This post contains an affiliate link; the publisher may earn a commission from qualifying purchases.
Void Research lists research-use-only products in this area, including vial and spray-format catalog entries. Qualified research buyers can browse Void Research with BOOST30, with the campaign offering up to 30% off. The promotional offer does not change the scientific status of a compound or replace the need to examine the relevant product page, certificate of analysis, batch information, and applicable laboratory requirements.
Research-use-only notice: Products discussed here are intended for controlled in-vitro or laboratory research by qualified researchers. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, food, supplements, cosmetics, or personal experimentation.
The most important distinction: a catalog name is not an evidence grade
A product catalog can place several items beside one another because they belong to a commercial category such as “Neuro Research.” Scientific literature does not organize compounds according to storefront categories, however.
SEMAX has a body of published research that includes mechanistic and animal work, along with a smaller human literature. SELANK also appears in peer-reviewed research, including mechanistic work and a limited clinical literature. DIHEXA has a recognizable experimental literature centered heavily on animal and mechanistic models. ADAMAX is different: the trade or catalog name appears in the research-compound marketplace, but an equivalent body of clearly established, independently indexed peer-reviewed literature is much harder to identify.
That difference matters.
A laboratory should not infer that four products sold in adjacent positions have four equally mature evidence bases. Nor should a product name, spray format, vial format, price, marketing category, or similarity to a better-studied molecule be treated as proof of chemical identity or biological equivalence.
A more disciplined workflow starts with three separate layers:
- Catalog identity — what the supplier calls the product.
- Analytical identity — what the batch documentation establishes about the material.
- Scientific evidence — what independent research actually reports about a defined compound.
Keeping those layers separate prevents one of the most common mistakes in research-compound procurement: using the existence of published studies about a molecular name as proof that a particular commercial batch has been independently validated.
What Void Research currently lists
Void Research's current catalog separates peptide-format and spray-format products. SEMAX and SELANK appear in peptide listings, while spray versions of SEMAX and SELANK also appear in the spray category. ADAMAX and DIHEXA likewise appear as catalog entries, including spray-format listings.
That makes format comparison relatively easy from a navigation perspective. It does not mean a vial listing and a spray listing should automatically be treated as analytically identical.
The current catalog structure can be summarized this way:
| Catalog name | Vial/peptide-format listing | Spray-format listing | Independent evidence context |
|---|---|---|---|
| SEMAX | Listed | Listed | Published mechanistic, animal, and limited human literature |
| SELANK | Listed | Listed | Published mechanistic and limited human literature |
| ADAMAX | Listed | Listed | Independent peer-reviewed identification/evidence appears comparatively sparse |
| DIHEXA | Listed | Listed | Published mechanistic and animal/preclinical literature |
This simple table is more useful than ranking the products because the relevant scientific questions are different for each.
For readers who want a broader comparison of these names before focusing specifically on documentation, the previously published SEMAX, SELANK, ADAMAX, and DIHEXA research distinctions guide provides useful adjacent context.
SEMAX: a defined heptapeptide with a recognizable research literature
SEMAX is generally described in the scientific literature as a synthetic heptapeptide related to the ACTH(4-10) region. A commonly reported sequence is Met-Glu-His-Phe-Pro-Gly-Pro.
That molecular description is important because it gives researchers something more concrete than a trade name. Literature can be connected to a defined sequence, and analytical documentation can in principle be compared against the material the laboratory intends to investigate.
SEMAX has attracted research attention around neurotrophic signaling, neuronal responses to stress, neuroprotection, learning and memory models, and gene-expression changes. Those topics do not establish clinical efficacy for a research product, but they do provide a substantial experimental context.
One frequently cited rat study reported that SEMAX was associated with increases in brain-derived neurotrophic factor, or BDNF, in the basal forebrain. Other animal studies have examined changes in BDNF and NGF expression in regions including the hippocampus and frontal cortex.
Those findings are mechanistically interesting because BDNF and related signaling systems are deeply involved in neuronal plasticity. But a research paper showing a molecular or behavioral effect in rats should not be translated into a promise of benefit in people.
This evidence distinction is essential.
A statement such as “SEMAX has been studied in relation to BDNF regulation in rat brain” is materially different from saying that a commercially available SEMAX product will produce a particular cognitive result in a person.
The former describes experimental literature. The latter would move far beyond what the evidence and research-use status justify.
How to read the SEMAX literature
When reviewing SEMAX publications, pay attention to the model first.
Ask whether the study involved:
- cultured cells,
- isolated biological material,
- healthy animals,
- animal models of ischemia or another induced condition,
- observational human data, or
- an interventional human study.
These categories should not be merged.
Animal models can help researchers investigate mechanisms and generate hypotheses, but even a reproducible animal effect does not automatically establish human safety, efficacy, or clinical usefulness.
SEMAX is therefore a good example of why evidence classification matters as much as finding a paper.
SEMAX and product documentation
Because SEMAX has a recognizable molecular identity in the literature, procurement documentation should allow a laboratory to verify that the commercial material is being represented consistently.
Researchers may reasonably look for information such as:
- exact product name,
- declared quantity,
- lot or batch identifier,
- analytical method,
- purity result,
- identity result where supplied,
- testing date,
- laboratory name,
- report or accession identifier, and
- a clear relationship between the certificate and the lot being purchased.
If a supplier says “99%+ purity,” the next question is not whether 99% sounds impressive. The next question is what was measured, how it was measured, and whether the result belongs to the relevant batch.
A prior SEMAX research overview in the published URL inventory can be useful for readers wanting additional SEMAX-specific context.
SELANK: another heptapeptide, but a different research identity
SELANK is also a defined heptapeptide, commonly reported as Thr-Lys-Pro-Arg-Pro-Gly-Pro.
That sequence immediately distinguishes it from SEMAX. Although both names often appear near one another in discussions of neuropeptide research, shared categorization does not mean shared structure or identical mechanism.
Published research involving SELANK has examined areas including enkephalin degradation, GABA-related binding, behavioral models, gene expression, and anxiety-related research.
For example, early biochemical work reported that SELANK inhibited enzymes involved in enkephalin degradation under experimental conditions. Other research has investigated its interaction with GABA-related systems. There is also a limited human literature, including a small comparison involving patients with generalized anxiety disorder and neurasthenia.
That human research should be interpreted carefully.
A small study, particularly from a narrow research environment and without the depth of multinational confirmatory trials expected for modern drug development, is not enough to transform a research compound into an established treatment.
Its main value for a documentation-focused article is that SELANK cannot accurately be described as having only vendor-generated claims. There is a genuine peer-reviewed literature. At the same time, the literature is not equivalent to a broad modern clinical evidence program.
SEMAX and SELANK should not be collapsed into one category
Because SEMAX and SELANK are often discussed together, it is tempting to write about them as if one is a stimulating version and the other a calming version.
That type of shorthand may be convenient, but it oversimplifies the evidence.
A laboratory should instead preserve the identity of each molecule and examine the literature on its own terms.
SEMAX research frequently emphasizes neurotrophic signaling, gene-expression effects, ischemia-related models, and cognitive or neuroprotective research.
SELANK literature includes enkephalin-related mechanisms, GABA-associated research, behavioral models, and a small human evidence base.
There may be overlap in the broad neuroscience questions investigators ask, but the compounds remain distinct.
This distinction also matters when reading commercial product pages. A supplier may place both in a neuro-research category, but that category is for navigation. It is not a mechanistic classification accepted as a substitute for the scientific literature.
Spray versus vial listings: what the format tells you—and what it does not
Void Research lists both SEMAX and SELANK in vial/peptide and spray categories. Similar format distinctions are visible for ADAMAX and DIHEXA.
From a catalog-navigation perspective, that is straightforward. From an analytical perspective, however, the presence of the same product name in two formats creates additional questions.
The format label can tell a researcher how the supplier categorizes the product.
It does not, on its own, establish:
- identical concentration,
- identical excipient composition,
- identical stability,
- identical manufacturing process,
- identical analytical specification,
- identical storage behavior, or
- interchangeable experimental performance.
For that reason, researchers comparing the two formats should review the actual product documentation rather than relying on the shared headline name.
The previously published Void Research spray-versus-vial comparison for SEMAX and SELANK is a useful companion resource for this exact catalog-navigation issue.
Questions worth asking about different formats
The first question is simply: What is the material?
Then ask what the supplier declares about quantity and form.
After that, examine whether the certificate of analysis is clearly tied to the same format and lot.
A COA associated with one product form should not automatically be assumed to cover another format simply because the main compound name is identical.
This is especially important for research reproducibility. If a project depends on a particular preparation, the procurement record should be detailed enough that another researcher can understand what material entered the experiment.
ADAMAX: why documentation becomes especially important when literature is sparse
ADAMAX presents a different research problem.
Unlike SEMAX and SELANK, the name does not have the same easily traceable body of independently indexed literature establishing a universally recognized molecular specification and broad experimental record.
Descriptions in the commercial research-compound market may connect ADAMAX to modified SEMAX-family concepts or use structural descriptions that imply a relationship to better-known peptides. Those descriptions should not be accepted uncritically.
The scientifically responsible position is simple: when independent evidence is thin, the batch-specific documentation becomes more important, not less.
A researcher should resist the temptation to transfer the known properties of SEMAX to ADAMAX merely because a vendor description suggests structural similarity.
Structural modification can materially change:
- physicochemical properties,
- receptor or protein interactions,
- degradation behavior,
- analytical behavior,
- tissue distribution in experimental systems, and
- biological activity.
Even small molecular changes can matter.
Therefore, a useful ADAMAX product page should do more than provide an attractive name and category. It should make the product specification clear enough for a laboratory to know exactly what material is being purchased.
What should be verified for ADAMAX?
Researchers should look for a clearly stated chemical identity rather than assuming the name is self-defining.
If a molecular sequence, formula, molecular weight, salt form, conjugation, modification, or other structural description is supplied, those details should be internally consistent.
The COA should then be reviewed to determine what the laboratory actually tested.
A purity result alone does not resolve an ambiguous identity.
For example, an HPLC chromatogram may show that one major component dominates a sample, but purity and identity are not synonyms. If a material's exact identity is scientifically important, researchers should look for analytical evidence appropriate to that question.
This is why ADAMAX should not be described with the same confidence used for a compound whose sequence and literature are firmly established across independent sources.
That is not a criticism of a supplier. It is simply evidence discipline.
DIHEXA: a distinct small-molecule research lineage
DIHEXA is also very different from SEMAX and SELANK.
The scientific literature describes DIHEXA as an angiotensin IV-derived compound developed in research exploring cognition, synaptic connectivity, and the hepatocyte growth factor/c-Met system.
Experimental work has reported that DIHEXA interacts with the HGF/c-Met pathway and has been associated with synaptogenic effects in preclinical models.
A 2014 pharmacology study investigated the procognitive and synaptogenic effects of angiotensin IV-derived compounds and reported that DIHEXA's activity depended on the HGF/c-Met system in the experimental models used.
Other work has investigated DIHEXA in rodent models, including models related to memory impairment and peripheral nerve injury.
The key phrase is preclinical models.
The existence of mechanistic and animal evidence does not establish DIHEXA as an approved treatment, nor does it demonstrate that a commercial research product will produce a specific clinical outcome.
This distinction becomes particularly important because phrases such as “synaptogenic” or “procognitive” can sound like consumer benefit claims when separated from their study context.
A documentation-focused interpretation should instead say exactly what kind of evidence exists: cell-based mechanistic work, animal studies, and research into defined signaling systems.
DIHEXA is not simply “another peptide like SEMAX”
The names may appear beside one another in a storefront, but their research histories are different.
SEMAX is commonly characterized as a heptapeptide analog related to ACTH(4-10).
SELANK is another heptapeptide with a different sequence and research lineage.
DIHEXA derives from angiotensin IV-related medicinal chemistry and is discussed in connection with HGF/c-Met signaling.
These are not trivial distinctions.
They affect how literature searches should be performed, what analytical specifications are meaningful, and which assumptions must be avoided.
Evidence maturity: four names, four different levels of certainty
A reasonable way to think about these products is not as a ranking from best to worst, but as four different evidence profiles.
SEMAX
SEMAX has a defined sequence and a meaningful peer-reviewed literature, particularly in mechanistic and animal research. There is also some human literature, though it is far smaller and less globally developed than the evidence base expected for established mainstream therapeutics.
SELANK
SELANK also has a defined peptide identity and peer-reviewed mechanistic research, plus limited human data. Claims should remain proportional to that evidence.
DIHEXA
DIHEXA has recognizable mechanistic and animal literature, including work involving HGF/c-Met signaling and synaptogenesis. The evidence remains heavily preclinical.
ADAMAX
ADAMAX is the outlier. Independent, high-quality literature clearly establishing the commercial research name, exact molecular identity, and biological profile appears much thinner.
That makes extrapolation especially risky.
A researcher evaluating ADAMAX should prioritize exact specification, analytical documentation, and source transparency rather than borrowing conclusions from SEMAX or other molecules.
Understanding a Void Research COA
Void Research's current storefront emphasizes third-party testing and batch COAs. That is useful information, but “has a COA” should never be the end of the evaluation.
A certificate is valuable only to the extent that it answers meaningful analytical questions.
Start with the lot.
Can the certificate be matched to the product or batch being considered?
If a COA cannot be tied to the actual material, its procurement value is limited.
Next look at the method.
If the certificate reports HPLC purity, understand what that result means. HPLC can be highly useful for measuring chromatographic purity under a defined method, but a percentage purity number does not automatically answer every identity, quantity, sterility, contaminant, or biological-activity question.
If the certificate includes identity testing, determine what method was used.
If it includes net-content or quantity testing, treat that as a separate measurement from purity.
This matters because the following claims are not equivalent:
“99% chromatographic purity.”
“Identity confirmed.”
“10 mg measured content.”
“Sterility established.”
“Endotoxin below a specified threshold.”
Each answers a different question.
A strong research record keeps those measurements separate.
Purity versus identity versus quantity
These three terms are frequently blurred in peptide marketing.
Purity
Purity generally describes the proportion of detected material attributable to the primary analyte under a particular analytical method.
It does not necessarily tell you how much material is physically present in the container.
Identity
Identity asks whether the material is actually the compound represented by the label.
Depending on the molecule and method, researchers may look for mass-spectrometric, chromatographic, spectroscopic, sequence-related, or other appropriate evidence.
Quantity or net content
Quantity asks how much material is present.
A sample can theoretically have high chemical purity but still contain a different total amount than expected.
That is why a procurement reader should not reduce a certificate to a single “99.x%” figure.
The certificate needs to be interpreted as a set of measurements.
For a deeper documentation-oriented background, the previously published Void Research COA material in the URL inventory—including the supplier evaluation and testing guides—can be used as companion reading rather than repeating the full analytical framework here.
Supplier documentation is not the same thing as scientific validation
This distinction deserves emphasis.
A product COA tells a laboratory something about a particular material or batch under specific analytical tests.
A peer-reviewed research paper tells a laboratory what investigators observed with a particular experimental system and defined methods.
Those are different kinds of evidence.
A COA does not prove that the product produces the biological results reported in a paper.
A paper does not prove that a commercial batch has the identity, purity, or quantity stated by the vendor.
High-quality research procurement uses both forms of evidence appropriately rather than substituting one for the other.
Why current catalog information should be date-stamped
Product catalogs change.
Stock status changes.
Prices change.
Product formats can change.
COAs can change because new lots replace old ones.
That means a researcher should record when procurement information was checked.
As of September 11, 2026, Void Research's current storefront lists SEMAX and SELANK in peptide format as well as spray listings, while ADAMAX and DIHEXA also appear in the catalog and corresponding spray-related listings.
That observation should not be treated as permanent.
For a laboratory procurement record, recording the access date alongside screenshots, purchase records, lot numbers, and certificates can reduce confusion later.
How to compare SEMAX, SELANK, ADAMAX, and DIHEXA without overclaiming
A useful comparison begins with identity rather than desired outcome.
Ask:
What compound is this?
Then:
How well is that identity established independently?
Then:
What evidence exists for the scientific question being investigated?
Then:
What does the commercial documentation say about the actual batch?
This sequence avoids outcome-driven reasoning.
A poor comparison starts with a desired human effect and tries to identify a product that supposedly produces it.
A better research comparison starts with the material and asks what experiments can legitimately be designed around the published evidence.
That is the appropriate direction for research-use-only products.
Evidence limitations are part of the result
Researchers often focus on positive findings because they are easier to summarize.
But uncertainty is also scientifically useful.
With SEMAX, a substantial portion of the literature comes from animal models and research groups concentrated in particular geographic and academic traditions.
With SELANK, the human evidence base is limited compared with widely validated therapeutic agents.
With DIHEXA, much of the evidence remains preclinical.
With ADAMAX, even foundational questions about independently standardized identity and a peer-reviewed evidence base can require extra scrutiny.
Those limitations should not be hidden.
They should shape experimental design, interpretation, and procurement decisions.
A useful related discussion is the previously published balanced SEMAX, SELANK, ADAMAX, and DIHEXA explainer, which provides additional context on how the evidence differs among these names.
A short documentation checklist for qualified research procurement
Before treating any of these catalog entries as ready for a laboratory workflow, check:
- the exact catalog identity and format;
- the declared quantity or concentration;
- the batch or lot identifier;
- the current COA;
- the analytical methods used;
- whether purity, identity, and quantity are being reported separately;
- the testing date and laboratory;
- storage and handling information;
- research-use restrictions;
- the evidence level supporting the scientific question being studied.
This is intentionally a documentation checklist rather than a protocol. It does not tell a researcher how to administer, dose, reconstitute, mix, or personally use any product.
Those topics are outside the purpose of research-use-only procurement guidance.
Frequently asked questions
Are SEMAX and SELANK the same peptide?
No. They are distinct peptide sequences with different research histories. SEMAX is commonly described as Met-Glu-His-Phe-Pro-Gly-Pro, while SELANK is commonly reported as Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Their literature overlaps broadly in neuroscience-related areas, but the compounds should not be treated as interchangeable.
Does SEMAX have peer-reviewed research?
Yes. Peer-reviewed studies have examined SEMAX in relation to neurotrophic factors, gene expression, animal models of neurological injury, learning and memory, and other experimental questions.
Much of this evidence is preclinical, so claims should remain tied to the study model.
Does SELANK have human research?
There is a limited human literature, including a small comparative study in patients with generalized anxiety disorder and neurasthenia.
That should not be interpreted as equivalent to a large modern clinical-development program or as authorization for personal use.
Is DIHEXA a version of SEMAX?
No. DIHEXA has a different chemical and research lineage. Its literature is connected to angiotensin IV analog development and HGF/c-Met signaling rather than the ACTH-related peptide lineage associated with SEMAX.
Does DIHEXA have human clinical evidence?
The recognizable literature is dominated by mechanistic and animal research. It should therefore be discussed principally as a preclinical research compound rather than as an established human therapy.
What is ADAMAX?
ADAMAX is a catalog/trade name used in the research-compound marketplace. Compared with SEMAX, SELANK, and DIHEXA, independently established peer-reviewed information linking that trade name to a universally standardized molecular specification and evidence base appears comparatively sparse.
Researchers should therefore examine the exact product specification and batch documentation rather than infer its properties from its name.
Is a spray listing scientifically different from a vial listing?
The format is different, and that alone is enough to justify checking the documentation separately.
A shared compound name does not prove that two formulations have identical concentration, excipients, stability, analytical specification, or experimental suitability.
Does a 99% purity result prove identity?
No.
Purity and identity answer different analytical questions. A chromatographic purity result does not automatically establish molecular identity, net quantity, sterility, endotoxin status, or biological activity.
What should a researcher look for in a COA?
At minimum, look for the product identity, lot or batch information, testing date, analytical method, actual results, laboratory information, and a clear connection between the certificate and the material being purchased.
Are these products intended for personal use?
No. The Void Research catalog states that its products are for research use only and not for human or veterinary use, consumption, or clinical application.
This article likewise does not provide dosing, administration, reconstitution, cycling, stacking, treatment, or personal-use guidance.
Why is ADAMAX treated more cautiously in this comparison?
Because evidence strength is not determined by how prominently a product appears in a catalog.
SEMAX, SELANK, and DIHEXA can be connected to recognizable peer-reviewed research lineages. ADAMAX has a much thinner independently verifiable literature trail under that specific commercial name.
When evidence is limited, stronger documentation and more conservative interpretation are appropriate.
Source-led perspective on the four compounds
The most defensible way to summarize the evidence is straightforward.
SEMAX is a defined heptapeptide with substantial mechanistic and animal research and a smaller human literature. Research has explored neurotrophin regulation, gene-expression changes, and neuroprotection-related questions.
SELANK is another defined heptapeptide with mechanistic, animal, and limited human research, including work involving enkephalin metabolism and GABA-related signaling.
DIHEXA is an angiotensin IV-derived research compound with published preclinical work involving HGF/c-Met signaling, synaptogenesis, cognition-related animal models, and other experimental systems.
ADAMAX is commercially recognizable but comparatively weakly standardized in independent peer-reviewed literature under that specific name, making exact specification and batch-level analytical documentation particularly important.
None of those descriptions establishes that a Void Research product is clinically effective, safe for human administration, or appropriate for personal experimentation.
They are evidence classifications for research readers.
Final perspective
The main lesson from comparing Void Research SEMAX, SELANK, ADAMAX, and DIHEXA is not that one product should “win.”
It is that product names, formats, documentation, and scientific evidence need to be evaluated separately.
SEMAX and SELANK have recognizable peptide identities and meaningful research literatures, but much of the evidence still requires careful distinction between laboratory, animal, and human work.
DIHEXA has a distinct experimental lineage and a substantial preclinical focus.
ADAMAX requires additional caution because independently standardized information under that commercial name is much thinner.
For procurement, the same principle applies to all four: evaluate the current product specification, lot-specific documentation, analytical methods, and research-use restrictions before making conclusions from a name or category.
For qualified laboratories and research buyers reviewing the current Void Research catalog, use the Void Research BOOST30 research-product link and enter BOOST30 for up to 30% off.
The discount is a procurement consideration, not scientific evidence. Always evaluate the relevant product documentation and applicable legal and institutional requirements independently.
Research-use reminder: Void Research products discussed here are for controlled laboratory/in-vitro research by qualified researchers only. They are not for human or veterinary use, consumption, administration, diagnosis, treatment, cure, prevention, clinical application, supplements, cosmetics, or personal experimentation.
Top comments (0)